![]() |
市场调查报告书
商品编码
1300005
基因组学服务市场 - 按服务(下一代测序、桑格测序、微阵列)、按应用(研究、诊断)、按终端用户(研究机构、诊断中心、合同研究组织(CRO)),预测-2032年Genomics Services Market - By Service (Next Generation Sequencing, Sanger Sequencing, Microarray), By Application (Research, Diagnostics), By End-user (Research Institutes, Diagnostic Centers, Contract Research Organization (CROs)), Forecast-2032 |
全球基因组学服务市场规模将在2032年之前呈指数级扩张。对药物基因组学的投资不断上升,增加了对基因组学服务的需求。通过将药物基因组学信息纳入药物开发和处方实践,基因组学服务有助于提高药物的疗效和安全性。识别影响药物反应的遗传标记,可以更好地为个别病人选择适当的药物、剂量和治疗方案。这种优化可以提高治疗效果,最大限度地减少药物的不良反应,并减少试验和错误的处方,从而导致基因组学服务的高采用率。
整个基因组学服务市场根据服务、应用、终端用户和地区进行分类。
基于服务,桑格测序部分的行业价值将在2032年之前观察到显著收益。桑格测序的高精确度有利于其采用。此外,对于规模较小的项目、低样本量或特定区域的定向测序,与高通量NGS平台相比,桑格测序可能是一个更实惠的选择。这种测序对于特定区域的定向测序或确认由其他方法确定的变体特别有用。
基于应用,从2023年到2032年,诊断领域的行业份额将以有利可图的复合年增长率增长。对精准医疗的认识不断提高,增加了诊断学中对基因组学服务的需求。通过分析病人的基因构成,包括生殖系和体细胞突变,基因组学服务可以帮助确定个性化的治疗方案。这包括确定目标疗法,预测药物反应,以及根据病人的基因组特征优化治疗方案。精准医疗的目的是通过根据个人的特定基因特征定制治疗方案来改善治疗效果。
基于终端用户,制药和生物技术公司部分的行业规模将在2032年之前显著扩大。制药和生物技术公司对药物开发的投资不断增长,增加了对基因组学服务的需求。这些服务有助于识别和验证药物开发的潜在治疗目标。通过分析来自患者、疾病模型或大规模基因组数据库的基因组数据,研究人员可以确定与疾病相关的遗传变异、突变或基因表达模式。
从区域来看,亚太地区的基因组学服务市场价值将在2023-2032年呈现出可观的增长。蓬勃发展的医疗保健行业,加上老年人口激增导致的慢性病的日益流行,增加了该地区对基因组学服务的投资。根据世界卫生组织,在中国,到2040年,60岁以上的人口将占人口的28%。此外,人们对基因组学的认识不断提高,也进一步促进了区域增长。
Global Genomics Services Market size will expand exponentially through 2032. Rising investments in pharmacogenomics have increased the demand for genomics services. By integrating pharmacogenomic information into drug development and prescribing practices, genomics services help improve drug efficacy and safety. Identifying genetic markers that influence drug response enables better selection of appropriate medications, dosages, and treatment regimens for individual patients. This optimization can enhance therapeutic outcomes, minimize adverse drug reactions, and reduce trial-and-error prescribing, leading to high adoption rate of genomics services.
The overall genomics services market is categorized based on service, application, end-user, and region.
Based on the service, industry value from the Sanger sequencing segment will observe significant gains through 2032. The high accuracy of Sanger sequencing favors its adoption. Additionally, for smaller-scale projects, low sample volumes, or targeted sequencing of specific regions, Sanger sequencing can be a more affordable option compared to high-throughput NGS platforms. This sequencing is particularly useful for targeted sequencing of specific regions or confirming variants identified by other methods.
Based on application, industry share from the diagnostics segment will grow at a lucrative CAGR from 2023 to 2032. Growing awareness about precision medicine has increased the demand for genomics services in diagnostics. By analyzing a patient's genetic makeup, including germline and somatic mutations, genomic services can help identify personalized treatment options. This includes identifying targeted therapies, predicting drug responses, and optimizing treatment regimens based on the patient's genomic profile. Precision medicine aims to improve treatment outcomes by tailoring therapies to an individual's specific genetic characteristics.
Based on end-user, industry size from the pharmaceutical & biotechnological companies segment will expand significantly through 2032. Growing investment in drug development by pharmaceutical and biotechnological companies has increased the demand for genomics services. These services help identify and validate potential therapeutic targets for drug discovery. By analyzing genomic data from patients, disease models, or large-scale genomic databases, researchers can identify genetic variants, mutations, or gene expression patterns associated with diseases.
Regionally, the Asia Pacific genomics services market value will show an appreciable growth over 2023-2032. Flourishing healthcare industry, coupled with the growing prevalence of chronic diseases attributed to the surging elderly population, has increased investments in genomics services in the region. As per WHO, in China, the population of people above 60 years will account for 28% of the population by 2040. Moreover, growing awareness about genomics is further contributing to regional growth.